Betadex Sulfobutyl Ether Sodium (CAS: 182410-00-0), also known as sulfobutyl ether β-cyclodextrin sodium salt, is a modified cyclodextrin derivative widely used as a pharmaceutical excipient to enhance the solubility, stability, and bioavailability of poorly water-soluble active ingredients.
Derived from β-cyclodextrin through sulfobutyl ether modification, this compound possesses a hydrophobic cavity and hydrophilic exterior, enabling it to form inclusion complexes with a broad range of drug molecules. The introduction of sulfobutyl ether groups significantly improves aqueous solubility and expands its compatibility with pharmaceutical formulations.
In pharmaceutical development, this excipient is particularly valuable for challenging compounds with limited solubility or stability. It has become an important tool in formulation research and is widely investigated for use in novel drug delivery technologies.
Beyond pharmaceutical applications, modified cyclodextrins are also explored in analytical chemistry, biotechnology, and specialty chemical fields due to their unique host–guest interaction capabilities.
UCHEM supplies Betadex Sulfobutyl Ether Sodium (CAS: 182410-00-0) with consistent quality and reliable availability, supporting pharmaceutical research, formulation development, and commercial manufacturing requirements.
